1454585-22-8Relevant academic research and scientific papers
Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer
Monastyrskyi, Andrii,Nilchan, Napon,Quereda, Victor,Noguchi, Yoshihiko,Ruiz, Claudia,Grant, Wayne,Cameron, Michael,Duckett, Derek,Roush, William
, p. 590 - 602 (2018)
Casein kinase 1δ/ε have been identified as promising therapeutic target for oncology application, including breast and brain cancer. Here, we described our continued efforts in optimization of a lead series of purine scaffold inhibitors that led to identification of two new CK1δ/ε inhibitors 17 and 28 displaying low nanomolar values in antiproliferative assays against the human MDA-MB-231 triple negative breast cancer cell line and have physical, in vitro and in vivo pharmacokinetic properties suitable for use in proof of principle animal xenograft studies against human cancers.
Structure-Based Design of Selective Noncovalent CDK12 Inhibitors
Johannes, Jeffrey W.,Denz, Christopher R.,Su, Nancy,Wu, Allan,Impastato, Anna C.,Mlynarski, Scott,Varnes, Jeffrey G.,Prince, D. Bryan,Cidado, Justin,Gao, Ning,Haddrick, Malcolm,Jones, Natalie H.,Li, Shaobin,Li, Xiuwei,Liu, Yang,Nguyen, Toan B.,O'Connell, Nichole,Rivers, Emma,Robbins, Daniel W.,Tomlinson, Ronald,Yao, Tieguang,Zhu, Xiahui,Ferguson, Andrew D.,Lamb, Michelle L.,Manchester, John I.,Guichard, Sylvie
, p. 231 - 235 (2018/02/06)
Cyclin-dependent kinase (CDK) 12 knockdown via siRNA decreases the transcription of DNA-damage-response genes and sensitizes BRCA wild-type cells to poly(ADP-ribose) polymerase (PARP) inhibition. To recapitulate this effect with a small molecule, we sought a potent, selective CDK12 inhibitor. Crystal structures and modeling informed hybridization between dinaciclib and SR-3029, resulting in lead compound 5 [(S)-2-(1-(6-(((6,7-difluoro-1H-benzo[d]imidazol-2-yl)methyl)amino)-9-ethyl-9H-purin-2-yl)piperidin-2-yl)ethan-1-ol]. Further structure-guided optimization delivered a series of selective CDK12 inhibitors, including compound 7 [(S)-2-(1-(6-(((6,7-difluoro-1H-benzo[d]imidazol-2-yl)methyl)amino)-9-isopropyl-9H-purin-2-yl)piperidin-2-yl)ethan-1-ol]. Profiling of this compound across CDK9, 7, 2, and 1 at high ATP concentration, single-point kinase panel screening against 352 targets at 0.1 μm, and proteomics via kinase affinity matrix technology demonstrated the selectivity. This series of compounds inhibits phosphorylation of Ser2 on the C-terminal repeat domain of RNA polymerase II, consistent with CDK12 inhibition. These selective compounds were also acutely toxic to OV90 as well as THP1 cells.
WEE1 DEGRADATION INHIBITORS
-
, (2013/09/12)
The invention provides compounds that inhibit the degradation of Weel. The compounds of the present invention are generally N-((1H-benzo[d]imidazol-2- yl)methyl)-9H-purin-6-amines. Compounds of the invention can be used for treatment of malconditions in p
